Innovations + Investments in Healthcare Summit 2015


AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit

Amgen RSS Channel

Title Filter      Display #  
# Article Title
1 European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
2 Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab
3 Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia
4 Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma
5 Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry
6 Amgen's third quarter 2013 revenues increased 10 percent
7 Amgen acquires Filgrastim franchise rights from Roche In 100 markets
8 Amgen successfully completes Onyx Pharmaceuticals tender offer
9 Amgen and ShanghaiTech University announce plans for Amgen China R&D center
10 Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
11 FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone
12 Amgen and Astellas announce Japan Alliance
13 Amgen and Zhejiang Beta Pharma announce planned joint venture in China
14 Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma
15 Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
16 Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion
17 Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
18 Cancer Support Community launches national program to assist patients with cancer
19 Amgen's first quarter 2012 revenue increased 9 percent to $4.0 billion
20 Amgen to acquire privately held KAI Pharmaceuticals
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]